title: Lysergic acid amide-induced posterior reversible encephalopathy syndrome with status epilepticus.
abstract: BACKGROUND
  Posterior reversible encephalopathy syndrome (PRES) is known to occur in association with several substances. However, lysergic acid amide (LSA) is not among the previously reported causes of PRES.
  
  
  METHODS
  We report on a patient with PRES presenting as convulsive status epilepticus associated with hypertensive encephalopathy after LSA ingestion. Magnetic resonance imaging was performed and catecholamine metabolites assayed.
  
  
  RESULTS
  The patient achieved a full recovery after aggressive antihypertensive therapy and intravenous anticonvulsivant therapy. The clinical history, blood and urinary catecholamine levels, and response to treatment strongly suggest that PRES was induced by LSA.
  
  
  CONCLUSIONS
  LSA, a hallucinogenic agent chiefly used for recreational purposes, should be added to the list of causes of PRES.
authors.affiliation: Service de Réanimation Polyvalente, Hôpital André Mignot, 78157, Le Chesnay, France. stlegriel@invivo.edu
authors.forename: Stephane
authors.initials: S
authors.lastname: Legriel
authors.forename: Fabrice
authors.initials: F
authors.lastname: Bruneel
authors.forename: Odile
authors.initials: O
authors.lastname: Spreux-Varoquaux
authors.forename: Aurelie
authors.initials: A
authors.lastname: Birenbaum
authors.forename: Marie Laure
authors.initials: ML
authors.lastname: Chadenat
authors.forename: François
authors.initials: F
authors.lastname: Mignon
authors.forename: Nathalie
authors.initials: N
authors.lastname: Abbosh
authors.forename: Matthieu
authors.initials: M
authors.lastname: Henry-Lagarrigue
authors.forename: Laure
authors.initials: L
authors.lastname: Revault D'Allonnes
authors.forename: Pierre
authors.initials: P
authors.lastname: Guezennec
authors.forename: Gilles
authors.initials: G
authors.lastname: Troche
authors.forename: Jean Pierre
authors.initials: JP
authors.lastname: Bedos
mesh_terms: D000328:Adult; D000927:Anticonvulsants / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000627:therapeutic use; D006213:Hallucinogens / Q000009:adverse effects*; D006801:Humans; D020343:Hypertensive Encephalopathy / Q000139:chemically induced* / Q000188:drug therapy / Q000473:pathology; D008238:Lysergic Acid Diethylamide / Q000009:adverse effects / Q000031:analogs & derivatives*; D008279:Magnetic Resonance Imaging; D008297:Male; D020127:Recovery of Function; D013226:Status Epilepticus / Q000139:chemically induced* / Q000188:drug therapy / Q000473:pathology
chemical_list: D000927:Anticonvulsants; D000959:Antihypertensive Agents; D006213:Hallucinogens; C016543:lysergamide; D008238:Lysergic Acid Diethylamide